Preclinical studies have shown that glucagon-like peptide-1 (GLP-1) receptor agonistshave a beneficial effect on weight loss in sarcopenic obesity (16); these agents also help mitigate skeletalmuscle atrophy by activating sirtuin 1 (SIRT1), which plays a crucial role in preventingage-related muscle atrophy (79).Weight loss induced by bariatric surgery has a consistent effect on adipose tissue mass.Its beneficial effect on muscle performance has been demonstrated in patients withobesity by comparing individuals who have undergone bariatric surgery with those whohave not. The gene discussed is SIRT1; the disease is muscle atrophy.